Merck KGaA (MRK) Given Consensus Recommendation of “Hold” by Brokerages

Merck KGaA (FRA:MRK) has been given a consensus rating of “Hold” by the twenty-two ratings firms that are presently covering the stock, Marketbeat reports. Twelve analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is €108.11 ($128.70).

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. set a €100.00 ($119.05) target price on Merck KGaA and gave the stock a “neutral” rating in a research report on Friday, September 29th. Oddo Bhf set a €125.00 ($148.81) target price on Merck KGaA and gave the stock a “buy” rating in a research report on Friday, September 29th. Warburg Research set a €115.00 ($136.90) target price on Merck KGaA and gave the stock a “buy” rating in a research report on Monday, October 2nd. Kepler Capital Markets set a €115.00 ($136.90) target price on Merck KGaA and gave the stock a “buy” rating in a research report on Wednesday. Finally, Commerzbank set a €109.00 ($129.76) target price on Merck KGaA and gave the stock a “neutral” rating in a research report on Friday, September 29th.

Shares of Merck KGaA (FRA:MRK) opened at €90.22 ($107.40) on Friday. Merck KGaA has a 1 year low of €87.33 ($103.96) and a 1 year high of €115.00 ($136.90). The firm has a market capitalization of $11,680.00 and a PE ratio of 21.13.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/19/merck-kgaa-mrk-given-consensus-recommendation-of-hold-by-brokerages.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply